Onco Actu du 22 septembre 2017

	1. Biologie
Characterization of a Slowly Proliferating Population of Melanoma Cells with High Metastatic Properties [Wistar Institute] “This concept may sound counterintuitive because we are used to the idea that cancer cells are highly proliferative. However, slowly proliferating melanoma cells are more aggressive and therefore the most dangerous ones.”
How Mouse Models Pave the Way to Precision Cancer Medicine [Cancer Research Catalyst] To promote research on these topics, the AACR is holding a special conference, Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond, in Orlando, Florida, Sept. 24-27.
	3.1 Prévention - Tabac
Smoking quit rates highest in 10 years [Cancer Research UK] George Butterworth, Cancer Research UK’s tobacco policy manager, welcomed the report and said some of the success can be attributed to e-cigarettes.
	4.7 Dép., diag. & prono. - Col de l'utérus
FDA to Hold Meeting on Home Collection of Pap Smears: Possible Broader Implications? [FDA Law Blog] The adoption of self-collection tests could expand the volume of HPV testing and Pap testing. Moreover, this creates a potential market opportunity for companies that can make the self-collection devices.
	5.1 Traitements - Pré-clinique
New Study Offers Novel Treatment Strategy for Patients with Colon Cancer [Boston University] The new findings, reported online in Oncogenesis, shed light on how IGPR-1 contribute to colon tumor growth and drug resistance.
	5.12.2 Immunothérapies - CAR-T
A New Model T on the Horizon? [Cell] A hundred years ago, Henry Ford’s Model T forever transformed the American way of living and going places. He did it with innovations and the achievement of large-scale, assembly-line manufacturing capability. Time will tell whether CAR-T will be a new “Model T” on the horizon and with what we already witnessed, there is much to look forward to.
	5.12.5 Immunothérapies - Pharma
Celgene-backed FLX picks CCR4 antagonist for clinical trials [FierceBiotech] FLX475 is set to become first to reach human testing. FLX thinks the drug can disrupt the barrier of regulatory T cells that accumulate around tumors and stop the immune system from performing its cancer killing duties.
	5.2.1 Pharma - Partenariats
Cancer biobank Indivumed and CRO Helomics team up on precision medicine [FierceBiotech] Indivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical data collected from patients around the world to help advance research in personalized cancer treatments.
	5.2.3 Pharma - économie
Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales [FiercePharma] Pfizer would like to stay ahead of its competitors by notching up another approval in a group where Opdivo and Yervoy haven’t yet trod.
Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst [FiercePharma] The breast cancer medication Ibrance has been the shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to raise the entire company’s fortunes.
	5.3.4 Traitements - AMM (FDA, EMA)
Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma [Roche] Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan.
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma [Merck] First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK.
	6. Lutte contre les cancers
Science Surgery: Will cancer ever be cured? [Cancer Research UK] Researchers aren’t on the hunt for a silver bullet against all cancers. Quite the opposite.
	6.11 Patients
Giving patients a cancer diagnosis—what we need is more time [BMJ Blogs] As any patient will tell you, being diagnosed with an illness requires you to become fluent in the language of your disease—and, as we all know from school, learning a new language is no easy feat.